Brian Park, PharmD

Drug Information Specialist https://www.pulmonologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Lung Infection

Pfizer-BioNTech COVID-19 Vaccine Shows 100% Efficacy in Adolescents

Brian Park, PharmD

April 6, 2021

A phase 3 trial evaluating the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, in adolescent participants 12 to 15 years of age demonstrated 100% efficacy and strong antibody responses.

Lung Infection

Trial Evaluating Tocilizumab Plus Remdesivir for COVID-19 Pneumonia Misses Endpoints

Brian Park, PharmD

March 22, 2021

The REMDACTA study evaluated the efficacy and safety of tocilizumab plus remdesivir in hospitalized patients with severe COVID-19 pneumonia receiving standard of care.

Lung Cancer

Trial Investigating Canakinumab for Advanced or Metastatic NSCLC Misses Primary Endpoint

Brian Park, PharmD

March 19, 2021

Canakinumab is a human monoclonal antibody that binds with high affinity and selectivity to interleukin-1beta.

Lung Infection

Real-World Data Demonstrate Effectiveness of Pfizer-BioNTech COVID-19 Vaccine

Brian Park, PharmD

March 18, 2021

The analysis was conducted when more than 80% of tested specimens in Israel were variant B.1.1.7 (UK variant).

Lung Cancer

Pembrolizumab Indication for Metastatic Small Cell Lung Cancer Withdrawn

Brian Park, PharmD

March 8, 2021

Continued approval of the indication was contingent upon establishing the superiority of Keytruda as determined by overall survival.

Lung Infection

NIH: COVID-19 Convalescent Plasma Unlikely to Benefit Patients With Mild Symptoms

Brian Park, PharmD

March 5, 2021

The trial enrolled 511 adult participants across 47 hospital emergency departments in the United States who had at least 1 risk factor for severe COVID-19.

Lung Cancer

Trilaciclib Now Available to Reduce Chemotherapy-Induced Bone Marrow Suppression in Extensive-Stage SCLC

Brian Park, PharmD

March 5, 2021

The approval was based on data from 3 randomized, placebo-controlled trials that included 245 adults with ES-SCLC.

General Pulmonology

Gefapixant Under Review for Refractory Chronic Cough

Brian Park, PharmD

March 4, 2021

The NDA submission is based on data from the double-blind, placebo-controlled phase 3 studies, COUGH-1 and COUGH-2.

General Pulmonology

FDA: Certain Factors May Affect Pulse Oximeter Accuracy

Brian Park, PharmD

February 24, 2021

According to the FDA’s safety communication, multiple factors may affect the accuracy of pulse oximeter readings, including poor circulation, skin pigmentation, skin thickness, skin temperature, current tobacco use, and use of fingernail polish.